Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.56 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | NAAA | Q02083 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | DGKA | P23743 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL175306 | 0.98 | — | — | |
| SCHEMBL11796411 | 0.95 | HTR2C (0.56) | HTR2CALDH1A1NAAAATMDGKA | |
| Glycine SCHEMBL6031569 | 0.94 | HTR2C (0.51) | HTR2CALDH1A1NAAAATMDGKA | |
| Glycine SCHEMBL6031573 | 0.94 | HTR2C (0.51) | HTR2CALDH1A1NAAAATMDGKA | |
| Hydrochloric Acid SCHEMBL716831 | 0.93 | HTR2C (0.65) | HTR2CALDH1A1NAAADGKATSHR | |
| Hydrochloric Acid SCHEMBL6689298 | 0.91 | HTR2C (0.68) | HTR2CALDH1A1NAAADGKATSHR | |
| Hydrochloric Acid SCHEMBL11130165 | 0.91 | HTR2C (0.68) | HTR2CALDH1A1NAAADGKATSHR | |
| Acetic Acid SCHEMBL21196854 | 0.91 | ALDH1A1 (0.56) | HTR2CALDH1A1NAAAATMDGKA | |
| Hydrochloric Acid SCHEMBL7346909 | 0.91 | HTR2C (0.68) | HTR2CALDH1A1NAAADGKATSHR | |
| Hydrochloric Acid SCHEMBL30559920 | 0.91 | HTR2C (0.68) | HTR2CALDH1A1NAAADGKATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118234709-A | Hydrophilic azadibenzocyclooctyne derivatives and metal-free click reactions with these hydrophilic azadibenzocyclooctyne derivatives | 豪夫迈·罗氏有限公司 | 2024-06-21 | — | — | CN | disclosed |
| EP-4294523-A1 | ARYLTHIOETHER ACETAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | X-Biotix Therapeutics, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| CN-110204484-B | The method comprises the following steps of 18 F-labeled fluoropyridine formylglycine, and preparation method and application thereof | 山西医科大学第一医院 | 2023-07-21 | — | — | CN | disclosed |
| WO-2022178228-A1 | ARYLTHIOETHER ACETAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | X-BIOTIX THERAPEUTICS, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| EP-3982948-A1 | LIPOSOME FORMULATION | Rosi Charni AS (NO) | 2022-04-20 | — | — | EP | disclosed |
| US-11229637-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210060000-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2021-03-04 | — | — | US | disclosed |
| WO-2020253824-A1 | 18F-LABELED FLUOROPICOLINYLGLYCINE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 山西医科大学第一医院 | 2020-12-24 | — | — | WO | disclosed |
| WO-2020251368-A1 | LIPOSOME FORMULATION | ROSI CHARNI AS (NO) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020236010-A1 | FATTY ACID COMPOUNDS FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS | T OMEGA AS (NO) | 2020-11-26 | — | — | WO | disclosed |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | FIBROGEN, INC. | 2004-12-16 | — | — | US | disclosed |
| EP-1242120-A2 | COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE | Pfizer Limited (GB) | 2002-09-25 | — | — | EP | disclosed |
| CN-1307560-A | Amidino and guanidino beta-azetidinone tryptase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2001-08-08 | — | — | CN | disclosed |
| WO-2001049309-A2 | COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE | PFIZER LIMITED (GB) | 2001-07-12 | — | — | WO | disclosed |
| CN-1057755-C | Process for preparing fluoroalkenyl compounds | MONSANTO CO (US) | 2000-10-25 | — | — | CN | disclosed |
| CN-1030527-C | Preparation of 2, 2, 3, 3-tetramethyl cyclopropane carboxylic acid | DALIAN CHEMICAL PHYSICS INST (CN) | 1995-12-20 | — | — | CN | disclosed |
| WO-1992016552-A1 | 1-IMIDAZOLGEMETHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF ANGIOTENSIN II ACTIVITY | GLAXO GROUP LIMITED (GB) | 1992-10-01 | — | — | WO | disclosed |
| EP-0505954-A1 | N-Imidazolylmethyl benzofuran derivatives as inhibitors of angiotensin II activity | GLAXO GROUP LIMITED (GB) | 1992-09-30 | — | — | EP | disclosed |
| CN-1062345-A | 2,2,3, the preparation of 3-Tetramethylcycloprop-ne-ne carboxylic acid | DALIAN INST OF CHEMICO PHYSICS (CN) | 1992-07-01 | — | — | CN | disclosed |
| US-4138414-A | 2-Phenoxy and 2-phenylthio anthraquinone disperse dyes | SANDOZ LTD. (CH) | 1979-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11229637-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | HTR2C 1175/4885PDE4D 2950/4885ALDH1A1 1476/4885 |
| US-20210060000-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN2, HIF1A | HTR2C 2021/4885PDE4D 1922/4885ALDH1A1 1674/4885 |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | EPOR, HIF1AN, HIF1A | HTR2C 4126/4885PDE4D 2159/4885ALDH1A1 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.